Late-Listed Patents Need "Careful Scrutiny" By FDA, Hatch And Waxman Say
This article was originally published in The Tan Sheet
Executive Summary
FDA should closely examine patents submitted for listing in the "Orange Book" in advance of generic competition, Sens. Edward Kennedy (D-Mass.) and Orrin Hatch (R-Utah) and Rep. Henry Waxman (D-Calif.) state in a letter to HHS Secretary Tommy Thompson.
You may also be interested in...
Patent Settlement Notification Supported By FTC Workshop Participants
Legislation to require notification of patent litigation settlements would be useful, provided practical challenges can be worked out, former FTC Bureau of Competition Assistant Director Richard Feinstein told a recent commission hearing on patent/antitrust issues
Patent Settlement Notification Supported By FTC Workshop Participants
Legislation to require notification of patent litigation settlements would be useful, provided practical challenges can be worked out, former FTC Bureau of Competition Assistant Director Richard Feinstein told a recent commission hearing on patent/antitrust issues
Patent Settlement Notification Supported By FTC Workshop Participants
Legislation to require notification of patent litigation settlements would be useful, provided practical challenges can be worked out, former FTC Bureau of Competition Assistant Director Richard Feinstein told a recent commission hearing on patent/antitrust issues